top of page
20/20 GeneSystems
Login to favorite a company
Early Cancer Detection. Powered by AI.
Most Recent Valuation:
$69,860,000.00
Legal Name:
Founded:
State of HQ:
20/20 GeneSystems, Inc.
9/28/2000
MD
Company Description
Employees:
[]
Funding Summary
Number of funding rounds
7
Total amount raised
$8,343,755
Round name | End date | Raised | Status | Type | Investment minimum | Valuation | Valuation Cap | Price per share |
|---|---|---|---|---|---|---|---|---|
20/20 GENESYSTEMS, INC.Preferred Stock 3 | $347,127.00 | open | Preferred Stock | $500 | $69,860,000 | |||
20/20 GeneSystems, Inc. Convertible Note 2 | 03/21/2023 | $232,186.66 | closed | Convertible Note | $500 | $58,400,000 | ||
Round 3 Reg A? https://www.sec.gov/cgi-bin/browse-edgar?CIK=1139685 | 06/16/2021 | $2,909,129.00 | closed | Common Stock | $502 | $38,500,000 | 4.4 | |
10/30/2020 | $3,791,881.00 | closed | Preferred Stock | $502 | $38,500,000 | 4.4 | ||
20/20 GeneSystems Reg A+ 3 | 05/16/2020 | $1,410,558.00 | closed | Preferred Stock | $502 | 4.4 | ||
20/20 GeneSystems Stock Reg A 2 | closed | Preferred Stock | 3.53 | |||||
20/20 GeneSystems Stock 1 | closed | Preferred Stock | 3.26 |
See round history
Round history
Round name | Perk description | Perk level (dollars) | Perk level (days) |
|---|
Loading...
Early Bird Perk history
Company notes
Type | Round name | Date Added | Date Updated | Notes |
|---|
Loading...
Financials (up to prior 4 years)
Revenue
COGS
Gross margin | (%)
Taxes
SG&A, other
Net income
Cash/Equivalents
Accounts Receiv
Other Assets
Assets
Short term debt
Long term debt
Equity/other liabilities
Gross margin, Other Assets, and Equity/other liabilities are derived from the financial statements of the company reported to the SEC. Assets = Liabilities + Equity, and no equity accounts nor accounts payable are reported to the SEC, hence the possibility for that amount to be either equity or a liability.
bottom of page